NCT01204658 - Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants | Biotech Hunter

Enrollment

576

Participants

Timeline

Start Date

September 27, 2010

Primary Completion Date

November 3, 2011

Study Completion Date

October 1, 2012

Conditions

Infections, Streptococcal

Interventions

BIOLOGICAL

Pneumococcal vaccine GSK 2189242A (LD formulation 1)

Intramuscular injection

BIOLOGICAL

Pneumococcal vaccine GSK 2189242A (HD formulation 2)

Intramuscular injection

BIOLOGICAL

Synflorix

Intramuscular injection

BIOLOGICAL

Prevenar 13

Intramuscular injection

BIOLOGICAL

Infanrix Hexa (DTPa-HBV-IPV/Hib)

Intramuscular injection

Trial Locations (24)

1600

GSK Investigational Site, Prague

13055

GSK Investigational Site, Berlin

32756

GSK Investigational Site, Detmold

37701

GSK Investigational Site, Jindřichův Hradec

46015

GSK Investigational Site, Liberec

50345

GSK Investigational Site, Wroclaw

67227

GSK Investigational Site, Frankenthal

74523

GSK Investigational Site, Schwäbisch Hall

78532

GSK Investigational Site, Tuttlingen

256 01

GSK Investigational Site, Benešov

613 00

GSK Investigational Site, Brno

405 01

GSK Investigational Site, Děčín

272 01

GSK Investigational Site, Kladno

547 01

GSK Investigational Site, Náchod

363 01

GSK Investigational Site, Ostrov

532 03

GSK Investigational Site, Pardubice

39-200

GSK Investigational Site, Dębica

31-503

GSK Investigational Site, Krakow

61-709

GSK Investigational Site, Poznan

41-103

GSK Investigational Site, Siemianowice Śląskie

01-184

GSK Investigational Site, Warsaw

SE-702 11

GSK Investigational Site, Örebro

SE-831 83

GSK Investigational Site, Östersund

SE-901 85

GSK Investigational Site, Umeå